Vaccine and viral vector manufacturing

The Artemis process team guides customers through the decision making process by finding out how much they need to produce, by when, and what is their current process.


Artemis VHU® perfusion technology is particularly suitable for ultra efficient manufacturing of labile viral vectors and viral vaccines from pilot to commercial scale. Perfusion with Artemis VHU technology can be done with any stand-alone or cell bag-based bioreactor. Only harvesting of the viral vectors and viral vaccines during the production phase is performed using our …

Perfusion Read More »